A phase II US safety study of Traumakine

Trial Profile

A phase II US safety study of Traumakine

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Interferon beta-1 (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions
  • Acronyms INTRUST
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 29 Mar 2017 According to a company media release, Faron plans to commence this safety study in H2 2017, which is expected to take 12 months to complete. The timing of this planned trial remains subject to regulatory approvals, with a pre-IND FDA meeting targeted to occur in mid 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top